Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

May 21, 2021

Study Completion Date

August 19, 2021

Conditions
SARS Virus
Interventions
DRUG

XAV-19

Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1

DRUG

Placebo

Phase 2a: Administration on Day 1 and day 5 for Group1 and 2, Administration on Day 1 for Group 3 Phase 2b: Administration on Day 1

Trial Locations (34)

Unknown

CHU Amiens Picardie, Amiens

CHU Angers, Angers

Hôpital Privé d'Antony, Antony

CH Avignon, Avignon

CH de la Côte Basque, Bayonne

APHP - Hôpital Avicennes, Bobigny

CHU Caen, Caen

CH Métropole Savoie, Chambéry

CH Colmar, Colmar

CH Sud Francilien, Corbeil-Essonnes

CHD Vendée, La Roche-sur-Yon

CH de La Rochelle, La Rochelle

CH Le Mans, Le Mans

CHRU Lille, Lille

CHU Limoges, Limoges

Hospices Civils Lyon, Lyon

CH de Mont de Marzan, Mont-de-Marsan

GHR Mulhouse Sud-Alsace, Mulhouse

CHU Nantes, Nantes

CHU Nice, Nice

CHU Nîmes, Nîmes

CHR Orléans La Source, Orléans

APHP - Hôpital Tenon, Paris

Hôpital Saint Antoine, Paris

CH René Dubos, Pontoise

CH Cornouaille, Quimper

CHU Reims, Reims

CHU Saint Etienne, Saint-Priest-en-Jarez

CHU Strasbourg, Strasbourg

Hôpital FOCH, Suresnes

CHRU Nancy, Vandœuvre-lès-Nancy

CH Bretagne Atlantique, Vannes

CHU Martinique, Fort-de-France

CHU La Réunion, Saint-Pierre

All Listed Sponsors
collaborator

BPIfrance

OTHER

collaborator

Xenothera SAS

INDUSTRY

lead

Nantes University Hospital

OTHER

NCT04453384 - Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia | Biotech Hunter | Biotech Hunter